6 results about "Fluvastatin" patented technology

A method of treating a wound may include topically administering a statin composition including a statin selected from atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combination thereof. The statin composition may be administered in an ointment, powder, or liquid format. The method may also include topically administering one or more antimicrobial drugs.

A method of treating a wound may include topically administering a statin composition including a statin selected from atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combination thereof. The statin composition may be administered in an ointment, powder, or liquid format. The method may also include topically administering one or more antimicrobial drugs and / or naltrexone.

The present invention is directed to solid, sustained-release, oral dosage form pharmaceutical compositions which contain therapeutic amount of a pharmaceutically acceptable salt of fluvastatin; hydroxypropyl methyl cellulose; and a non-ionic, hydrophilic polymer selected from the group consisting of hydroxyethyl cellulose having a number average molecular weight ranging from 90,000 to 1,300,000, hydroxypropyl cellulose having a number average molecular weight of 370,000 to 1,500,000, and poly(ethylene oxide) having a number average molecular weight ranging from 100,000 to 500,000 for the reduction of plasma cholesterol levels.

A method of treating a wound may include topically administering a statin composition including a statin selected from atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combination thereof. The statin composition may be administered in an ointment, powder, or liquid format. The method may also include topically administering one or more antimicrobial drugs and / or naltrexone.

This invention relates to the field of biomedical technology. It provides a pharmaceutical composition comprising fluvastatin and tanshinone as active ingredients, and further provides its application in the preparation of formulations for the prevention and / or treatment of radiation-induced lung injury. This invention utilizes the synergistic effect of fluvastatin and tanshinone to intervene in the pathogenesis of radiation-induced lung injury from multiple targets and pathways, significantly improving prevention and treatment efficacy. It can alleviate the inflammatory symptoms of radiation-induced pneumonia and delay the progression of radiation-induced pulmonary fibrosis, with low side effects, high safety, and wide applicability, providing a new drug option and technical solution for the clinical prevention and treatment of radiation-induced lung injury.

The present invention is directed to a solid, sustained-release, oral dosage form pharmaceutical composition which contains a therapeutic amount of fluvastatin,hydroxypropyl methyl cellulose and a non-ionic, hydrophilic polymer selected from the group consisting of hydroxyethyl cellulose having a number average molecular weight ranging from 90,000 to 1,300,000, hydroxypropyl cellulose having a number average molecular weight of 370,000 to 1,500,000, and poly(ethylene oxide) having a number average molecular weight ranging from 100,000 to 500,000.